Printer Friendly

Kymab and Roche sign clinical trial agreement.

M2 EQUITYBITES-June 28, 2018-Kymab and Roche sign clinical trial agreement


Biopharmaceutical company Kymab Group Ltd has entered into an agreement with F. Hoffmann-La Roche Ltd, part of the Roche Group (VTX: ROG), regarding its upcoming clinical trial, the company revealed on Thursday.

Under the agreement, Roche will provide its PD-L1 blocking antibody atezolizumab (TECENTRIQ) for use in Phase I/II clinical studies together with Kymab's lead investigational anti-ICOS antibody therapy, KY1044, in patients with advanced solid cancers. This will be the first study to combine an anti-ICOS antibody with an anti-PD-L1 antibody.

KY1044 is designed to both deplete intratumoral Regulatory T cells and stimulate T Effector cells to enhance the immune response against tumours.

Kymab plans to conduct Phase I/II studies of KY1044 in a variety of solid tumours both as monotherapy and in combination with atezolizumab.

Kymab will be responsible for conducting the clinical trials, which are anticipated to start in the second half of 2019.

Both companies will share data from the trials and Kymab will retain all commercial rights to KY1044.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 28, 2018
Previous Article:Mountain Province provides update of fifth successful diamond sale of 2018.
Next Article:Bear Creek Mining awarded Process Plant Construction Permit for Corani project in southern Peru.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters